Latest Headlines

Latest Headlines

Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug

One of Agios Pharmaceuticals' blood cancer treatments demonstrated promise in a Phase I study against solid tumors, but the results fell short of some investors' expectations, sending the company's share value down about 10%.

Patent challenger Bass wins IP reviews for Celgene, Shire meds

Chalk up a win for pharma patent challenger Kyle Bass. The U.S. Patent and Trademark Office has agreed to institute trials for 6 of the drug patents he's challenged--and IP shields for Celgene's Revlimid and Shire's Gattex are among them.

Celgene continues to see positive results for blockbuster hopeful Ozanimod

Celgene says that its blockbuster hopeful Ozanimod continued to score well against a placebo arm during the maintenance phase of a trial for ulcerative colitis.

Trial shows Celgene's oral psoriasis med works on patients who took Amgen's injectable Enbrel

Celgene touted postmarket study results of its oral antipsoriasis drug Otezla, which showed that the med works on those who switch over from Pfizer and Amgen's injectable competitor Enbrel (etanercept). Celgene's med is taking on a top dog in Enbrel, whose 2013 sales ($8.8 billion) made it the world's second best selling drug.

Australia's Mesoblast reaches milestone on Temcell with Japan partner JCR

Australia's Mesoblast will make the leap from drug discovery as Japanese partner JCR Pharmaceutical received approval to begin sales of an off-the-shelf allogeneic, or regenerative, medical product, Temcell, based on Mesoblast technology, the  Sydney Morning Herald  reports.

Celgene's Abraxane takes another hit from cost-effectiveness gatekeepers

Celgene's Abraxane can't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicated Cancer Drugs Fund, the treatment got another thumbs-down from its official cost-effectiveness watchdogs.

Third Rock's Nurix inks a $150M immuno-oncology pact with Celgene

Third Rock Ventures startup Nurix is lending its drug-development prowess to Celgene in exchange for $150 million up front and much more down the line, collaborating on potential treatments for cancer and immunology.

Celgene antes up $25M for first seat at antibody engineers' new deal table

Celgene is anteing $25 million to take the first seat at the players' table for a new academic research consortium that will put their combined antibody engineering platform to work finding next-gen anticancer therapies with commercial potential.

On a crash course with Celgene? Biogen inks a $544M autoimmune drug deal

After suffering back-to-back R&D and franchise setbacks, Biogen is beefing up its pipeline with a late-stage autoimmune drug, handing over $60 million in cash and promising up to $484 million in milestones to complete the pact with Mitsubishi Tanabe.

Roche CEO lashes out at U.K.'s 'stupid' move to stop paying for a dozen-plus cancer meds

The U.K.'s special cancer drugs fund gave the heave-ho to a slate of treatments, including Roche's cutting-edge breast cancer treatment Kadcyla and Celgene's Abraxane for pancreatic cancer. Drugmakers are hopping mad, cancer treatment charities are despairing--and the fund and some public officials are on the defensive.